Serum homocysteine level is higher in Behçet’s disease with vascular involvement

Ateş, Aşkın; Aydıntuğ, Olcay; Ölmez, Ümit; Düzgün, Nurşen; Duman, Murat

doi:10.1007/s00296-003-0398-9

Cited by 44 publications

(29 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the association between hcy and thrombosis remains statistically significant in many of the studies that considered in the analysis the impact of other potential risk factors, such as male sex or smoking habits. 8,12,25,[27][28][29][30]32,34,35 Furthermore, hcy appeared to be a risk factor for thrombosis even in the 2 studies in which immunosuppressive therapy had been withdrawn before measurement. 28,36 Third, 3 studies 4,25,28 have included also some patients with aneurysms as vascular manifestations.…”

Section: Discussionmentioning

confidence: 99%

“…Exclusion criteria were reported in 13 studies, 4 of them specified that patients taking drugs interfering with hcy levels were excluded. Thus, 4 studies were considered of high quality, 4,24,25,28 whereas the other 12 were considered of low quality. 8,12,26,27,29 -36 Hyperhomocysteinemia Eight studies, 4,12,26,27,30,32,35,36 for a total of 166 patients with thrombosis and 318 patients without thrombosis, were included in the metaanalysis.…”

Section: Study Qualitymentioning

confidence: 99%

“…Eleven studies, 4,8,12,24,25,[27][28][29][30]32,36 for a total of 236 patients with thrombosis and 518 patients without thrombosis, were included in the metaanalysis. In these patients, mean levels of hcy were significantly higher in patients with thrombosis compared with patients without thrombosis (mean difference 3.30 mol/L; 95% CI 2.09 to 4.51; Figure 3), again suggesting an association between the high levels of hcy and the development of thrombosis.…”

Section: Mean Levels Of Homocysteinementioning

confidence: 99%

See 2 more Smart Citations

Homocysteine in Vascular Behçet Disease

Regina

Orlandini

Prisco

et al. 2010

ATVB

View full text Add to dashboard Cite

Objective-Behçet disease (BD) is a vasculitis of unknown etiology, characterized by oral or genital aphtosis and uveitis.Homocysteine (hcy) is an independent risk factor for venous and arterial thrombosis. The association between hyperhomocysteinemia and thrombosis has been investigated in some studies in BD patients. However, information on this association is based only on the results of small studies with conflicting results. To overcome such limitations, we performed a metaanalysis comparing the plasma levels of hcy in BD patients with and without history of thrombosis. Methods and Results-We searched for all published studies using the Medline and Embase databases. Two reviewers performed study selection independently. Studies were included if hcy was measured in adult BD patients with and without thrombosis. Two reviewers independently extracted data on study and population characteristics. The mean value of hcy in BD patients and the presence of hyperhomocysteinemia in patients with and without thrombosis were collected. Association between thrombosis and hyperhomocysteinemia, and the mean difference of hcy levels in BD patients with and without thrombosis were calculated. Sixteen studies, for a total of 979 patients, were included. Hyperhomocysteinemia was more prevalent in patients with thrombosis than in those without (odds ratio 3.14; 95% CI 1.26 to 7.80) Mean levels of hcy were significantly higher in patients with thrombosis in comparison with patients without (mean difference 3.30 mol/L; 95% CI 2.09 to 4.51). This high prevalence of thromboses, known since the 1950s, 3 promoted several studies aimed at investigating their pathobiology. Endothelial injury itself, common to other vasculitis, cannot clearly account for thrombosis development, so a hypercoagulable state was early hypothesized and investigated. 4 In the last several years, several inherited or acquired factors causing hypercoagulability have been studied in patients with venous and arterial thromboembolic events. 5-7 These thrombophilic factors have also been studied in patients with BD with a history of thrombosis, and conflicting results were obtained. 8 -11 Recently, Ricart et al performed a metaanalysis evaluating the role of FV Leiden, prothrombin G2021A mutation, and the homozygous 677TT mutation of the methyltetrahydrofolate reductase as risk factors for venous thrombosis in BD patients. 12 In this study, FV Leiden and G2021A prothrombin mutation were found to increase the risk of thrombosis in these patients, whereas 677TT mutation of methyltetrahydrofolate reductase did not. Conclusion-OurThese findings are consistent with the results of recent studies performed in general populations in which the presence of 677TT mutation of methyltetrahydrofolate reductase is not a risk factor for venous thromboembolism in the absence of hyperhomocysteinemia. 13 On the other hand, in the general population, increased levels of homocysteine (hcy) have been reported to be an independent risk factor for venous thromboembolism in addition to c...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Study Qualitymentioning

confidence: 99%

Section: Mean Levels Of Homocysteinementioning

confidence: 99%

See 1 more Smart Citation

Homocysteine in Vascular Behçet Disease

Regina

Orlandini

Prisco

et al. 2010

ATVB

View full text Add to dashboard Cite

show abstract

“…16,17 Elevated Hcy has also been reported to be associated with thrombosis in vascular BS in several studies. [18][19][20][21] Cerebral venous sinus thrombosis frequently co-occurs with peripheral venous vascular events such as deep venous thrombosis and pulmonary vascular disease; therefore, serum Hcy levels are expected to be high in vascular NBS. 22 Homocysteine is known to be toxic for endothelial cells and has also been found to be associated with lower cognitive scores and neurological disorders.…”

Section: Discussionmentioning

confidence: 99%

Serum Vitamin B12, Homocysteine and Methylmalonic Acid Levels in Patients With Parenchymal Neuro-Behçet’s Syndrome

et al. 2017

View full text Add to dashboard Cite

Objectives: This study aims to investigate the role of serum levels of vitamin B12 (VitB12), homocysteine (Hcy), and methylmalonic acid (MMA) in the development of parenchymal neuro-Behçet's syndrome (NBS) and to compare them with healthy controls and Behçet's syndrome (BS) patients without NBS. Patients and methods: Serum VitB12, Hcy, and MMA were measured using enzyme-linked immunosorbent assay in 64 patients (36 males, 28 females; mean age 36±8.3 years; range 20 to 56 years) who met the criteria of the International Study Group for Behçet's Disease and 30 matched healthy controls (17 males, 13 females; mean age 35.76±9.6 years; range 20 to 50 years). The study participants were grouped as BS patients with NBS, BS patients without NBS, and healthy controls. Results: There was no significant difference between the groups regarding serum VitB12, Hcy, and MMA levels (p>0.05). Serum VitB12 levels were below the lower limit and serum Hcy levels were above the upper limit in all participants. MMA levels were normal in all participants. There was no correlation between the serum levels of VitB12, Hcy, and MMA and disease activity (p>0.05). Conclusion:The results of this study suggest that there is no significant association between VitB12 deficiency and parenchymal NBS. Further studies are needed to investigate the underlying mechanisms of the variable effects of VitB12 deficiency on different clinical manifestations of BS.

show abstract

“…The increased E-selectin levels were associated with Behçet's disease particularly the eye, central nervous system involvement, and thrombosis activation [28]. Increases in homocysteine levels have been demonstrated in Behcet;'s disease patients in which thrombosis has developed, and it has been suggested that the level is more related to endothelin and nitric oxide [29,30]. Plasminogen activator inhibitor-1 levels were increased in thrombosis and arthritis atacks in Behçet's disease [31].…”

Section: Behcet's Diseasementioning

confidence: 99%

Activity Criteria in Behçet’s Disease

Gül¹,

Nazik²,

Çiçek³

et al. 2017

Behcet's Disease

View full text Add to dashboard Cite

Behçet's disease is a complex disease characterized by remission and activation periods of unknown duration. It has an unpredictable course. Behçet's disease shows a heterogeneous patern of organ involvement that occurs in recurrent episodes of acute inlammation throughout the course of the disease. Disease activity in Behçet's disease is diicult to deine because of its luctuating course, lack of laboratory tests relecting overall disease activity, absence of a standardized form to report the severity of Behcet's disease manifestations and also trying to develop new diagnostic criteria. This led to the development of standardized disease activity index. To be useful, a measurement of disease activity must be valid, reliable, and simple enough to use in routine clinical practice. We will try to explain what the situation is in terms of Behçet's disease activity index.

show abstract

Serum homocysteine level is higher in Behçet’s disease with vascular involvement

Abstract: This preliminary study suggests that elevated serum homocysteine levels may play some role in the development of venous and arterial thromboses in BD.

Cited by 44 publications

References 15 publications

Homocysteine in Vascular Behçet Disease

Homocysteine in Vascular Behçet Disease

Serum Vitamin B12, Homocysteine and Methylmalonic Acid Levels in Patients With Parenchymal Neuro-Behçet’s Syndrome

Activity Criteria in Behçet’s Disease

Contact Info

Product

Resources

About